Revance Therapeutics, a biotechnology company focused on
innovative aesthetic and therapeutic offerings, today announced
that Fortune has recognized Revance on its 2021 Best Workplaces in
Health Care & Biopharma™ list.
Revance ranked No. 8 in the biopharma category. Fortune
partnered with Great Place to Work® on the ranking, which
considered more than 825,000 anonymous employee surveys from
companies across the health care and biopharma industry. Companies
were evaluated on more than 60 elements of employees’ experience on
the job, including their trust in leadership and workplace
culture.
“We believe that our people are our greatest asset and this
recognition underscores our efforts in creating a high-performing
culture and work environment that is diverse, inclusive, rewarding
and empowering,” said Mark Foley, President and Chief Executive
Officer of Revance. “We’re especially proud to share this
recognition with our employees following a year where we have both
doubled in size and adapted to a remote work environment given the
challenges resulting from the COVID-19 pandemic. I would like to
thank all of our employees for their perseverance and commitment to
maintaining our positive workplace culture during these trying
times while successfully delivering on our corporate
objectives.”
“Revance has a strong, dynamic culture that we continue to build
upon as we grow our business,” said Justin Ford, Senior Vice
President, Human Resources and Head of People at Revance. “We
believe that the beauty of the world lies in the diversity of its
people, and it is this mindset that pushes our culture to be the
foundation of our growth and success. Advancing employee
engagement, promoting open and honest feedback, hiring great
talent, creating an inclusive environment where people can grow and
develop and supporting the communities where our people live and
work, will continue to anchor our cultural initiatives.”
Revance has been certified by Great Place to Work® for three
consecutive years and this is the first year the company was
included in the Fortune 2021 Best Workplaces in Health Care and
Biopharma™ list.
The Fortune 2021 Best Workplaces in Health Care and Biopharma™
list is published here:
https://www.greatplacetowork.com/best-workplaces/health-care/2021?category=biopharma.
For more information on Revance’s culture, please visit:
https://www.revance.com/careers/culture/.
About the Fortune Best Workplaces in Health Care and
Biopharma™:
To determine the Fortune 2021 Best Workplaces in Health Care and
Biopharma™ list, Great Place to Work® analyzed anonymous survey
feedback representing over 825,000 employees working in the Health
Care & Biopharma industries in the United States.
Employees responded to over 60 survey questions describing the
extent to which their organization creates a Great Place to Work
For All™. Eighty-five percent of the evaluation is based on what
employees say about their experiences of trust and reaching their
full human potential as part of their organization, no matter who
they are or what they do. Great Place to Work analyzes these
experiences relative to each organization’s size, workforce make up
and what’s typical relative to their peers in the industry.
The remaining 15 percent of the rank is based on an assessment
of all employees’ daily experiences of innovation, the company’s
values, and the effectiveness of their leaders, to ensure they’re
consistently experienced.
To be considered, companies had to meet the Great Place to
Work-Certified standard. To ensure survey results truly represent
all employees, Great Place to Work requires that Trust Index©
survey results are accurate to a 95% confidence level with a 5%
margin of error or better. We review any anomalies in survey
responses, news and financial performance to ensure there aren’t
any extraordinary reasons to believe we couldn’t trust a company’s
survey results. Health Care companies with 10 to 999 people were
considered for the small and medium health care category, health
care companies with 1,000 employees or more were considered for the
large health care category, Biopharma companies with 10 or more
employees were considered for the Biopharma category, and those
that appear on Fortune’s 100 Best Companies to Work For list in
their respective industry category are ranked first.
About Great Place to Work®:
Great Place to Work® is the global authority on workplace
culture. Since 1992, they have surveyed more than 100 million
employees around the world and used those deep insights to define
what makes a great workplace: trust.
Great Place to Work helps organizations quantify their culture
and produce better business results by creating a high-trust work
experience for all employees. Everything they do is driven by the
mission to build a better world by helping every organization
become a Great Place to Work For All™.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation neuromodulator product, DaxibotulinumtoxinA for
Injection. DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval. Revance is also evaluating
DaxibotulinumtoxinA for Injection in the full upper face, including
glabellar lines, forehead lines and crow's feet, as well as in two
therapeutic indications - cervical dystonia and adult upper limb
spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance
owns a unique portfolio of premium products and services for U.S.
aesthetics practices, including the exclusive U.S. distribution
rights to the RHA® Collection of dermal fillers, the first and only
range of FDA-approved fillers for correction of dynamic facial
wrinkles and folds, and the HintMD fintech platform, which includes
integrated smart payment, subscription and loyalty digital
services. Revance has also partnered with Viatris (formerly Mylan
N.V.) to develop a biosimilar to BOTOX®, which would compete in the
existing short-acting neuromodulator marketplace. Revance is
dedicated to making a difference by transforming patient
experiences. For more information or to join our team visit us at
www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210322005729/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
626-589-1007 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com or General Media: Goodfuse: Jenifer Slaw,
347-971-0906 jenifer.slaw@Goodfuse.com or Trade Media:
Nadine Tosk, 504-453-8344 nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2023 to Sep 2024